CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Tauriga Sciences Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Tauriga Sciences Inc
4 Nancy Court, Suite 4
Phone: (917) 796-9926p:917 796-9926 WAPPINGERS FALLS, NY  12590  United States Fax: (514) 840-3698f:514 840-3698
On 5/3/2024, the Securities and Exchange Commission (SEC) charged BF Borgers CPA PC and its owner, Benjamin F. Borgers, with significant violations of Public Company Accounting Oversight Board (PCAOB) standards across more than 1,500 SEC filings from January 2021 to June 2023. The charges included falsely representing compliance with PCAOB standards to clients, fabricating audit documentation, and inaccurately stating compliance in audit reports. According to the SEC's order, of 369 BF Borgers' clients whose public filings from January 2021 through June 2023 incorporated the firm's audits and reviews, at least 75 percent of the filings incorporated audits and reviews that did not comply with PCAOB standards. The financials in this report may include past audits and reviews conducted by BF Borgers CPA PC that are deemed not compliant with PCAOB standards.
This company is no longer actively traded on any major stock exchange.
Business Summary
Tauriga Sciences, Inc. is a science, technology and consumer products company. The Company operates through its subsidiary, Tauriga Pharma Corp., which is focused on the development of a pharmaceutical product line that is synergistic with the Company’s primary Cannabidiol (CBD) product line. The Company operates through two segments. The first division consists of all retail, wholesale and e-commerce product sales of CBD/CBG Tauri-Gum, Tauri-Gummies, and other CBD/CBG products. The second segment is the research and development division, which consists of liabilities and results from any activity relative to the progress in the development of the Company’s Food and Drug Administration (FDA) and Investigational New Drug (IND) application for Phase II Trial of its proposed pharmaceutical-grade version of Tauri-Gum. It also developed an immune booster version of Tauri-Gum chewing gum. This product contains 60 milligrams (mg) of Vitamin C and 10mg of Elemental Zinc per piece.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20213/31/2021YesYes---

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer Seth M.Shaw 42 7/9/2015 8/22/2012
Chief Financial Officer Kevin P.Lacey 53 7/5/2017 7/5/2017
Director Thomas J.Graham 72 8/4/2015 8/4/2015
Director ChrisSferruzzo 43 3/8/2021 3/8/2021
Independent Director James V.Rosati 71 3/8/2021 3/8/2021

General Information
Number of Employees: 3 (As of 3/31/2014)
Outstanding Shares: 299,908,214 (As of 2/15/2022)
Shareholders: 1,211
Stock Exchange: OTC
Federal Tax Id: 651102237
Fax Number: (514) 840-3698


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, October 30, 2024